UCB: September 2017

UCB: September 2017

Atlanta, Georgia
Delivering value to patients.

As a global biopharmaceutical research company, UCB is committed to making an impact on the lives of patients and those who care for them, particularly in the areas of neurology, immunology, and bone. UCB is inspired by patients and driven by science. At UCB, everything starts with a simple question: “how will this deliver value to patients living with severe diseases?” The world’s fifth largest biopharmaceutical company, UCB has two sites in the U.S. – a U.S. corporate headquarters in Atlanta, Georgia and clinical development in Research Triangle Park in North Carolina.

As a global biopharmaceutical research company committed to delivering value to patients, research and innovation are critical to UCB’s success. To do this, UCB engages with patients, their families, and health care professionals. “We listen and we work collaboratively to address patients’ unmet needs,” said Patty Fritz, vice president, corporate affairs at UCB. “At UCB we want to enhance our understanding of disease and the real-life experiences of patients so our teams can deliver the right medicine and the right care to the right patient at the right time.”

UCB has more than 7,000 employees around the world working to deliver value to patients. As a company, UCB invests more than a quarter of its revenue back into research and development.

For UCB, creating value for patients means finding unique outcomes that help patients achieve their goals. To do this, and support patients and caregivers on their journey to have the best individual experience, their aim is to address outcomes that matter to people where UCB’s medicines are likely to be most effective. UCB is continuously working to advance science and embrace new knowledge, leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Recognizing there is no such thing as an average patient, UCB uses all the tools, channels, and scientific and technological advances available to develop a better understanding of the expressions of disease and embed the real needs of specific patient populations in the science and innovation process. UCB’s unique patient value model starts with patient needs to inform scientific discovery to develop innovative solutions to deliver to patients.

Open innovation is a key component of UCB’s success. By engaging through a model of open innovation, sharing knowledge among experts, they can more rapidly grow scientific understanding. As one example, UCB is partnering with scientists and leading universities, including Harvard, Baylor, and Cornell, to uncover the therapeutic tools needed to create new medicines. Instead of one-off partnerships that end, these are ongoing collaborations for the long haul with the original investigators.

“To be successful, partnership and collaboration are critical. Our scientists collaborate with leading researchers from academia and industry to advance science,” Fritz continued. She reiterated the importance of working together across the private and public sectors to have the greatest impact for patients. Fritz concluded, “That’s why organizations like Research!Americachampioning the importance of research in the health care ecosystem and the development and delivery of new medicines for patients is so important. We are proud to support Research!America’s work advocating for and advancing health research.”

For more information, visit www.ucb-usa.com(link is external)

Media Contacts

Tim Haynes
Senior Director of Communications 

If concerted, long-term investments in research are not made, America will lose an entire generation of young scientists.
Brenda Canine, PhD; McLaughlin Research Institute, Montana